
Editas Medicine Inc
NASDAQ:EDIT

ROA
Return on Assets
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
ROA Across Competitors
Country | Company | Market Cap | ROA | ||
---|---|---|---|---|---|
US |
![]() |
Editas Medicine Inc
NASDAQ:EDIT
|
129.7m USD |
-71%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-391%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
323.7B USD |
3%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
146.1B USD |
7%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
133.7B USD |
11%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112B USD |
-4%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-67%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
119.3B AUD |
7%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.7B USD |
13%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-21%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
37.8B USD |
-7%
|
Editas Medicine Inc
Glance View
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.

See Also
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
Based on Editas Medicine Inc's most recent financial statements, the company has ROA of -71.4%.